Rossella Medori

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
    Rossella Medori
    Janssen Cilag EMEA, Neuss, Germany
    Biol Psychiatry 63:981-9. 2008
  2. ncbi request reprint Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable
    Rossella Medori
    Janssen Cilag, Medical Affairs EMEA, Beerse, Belgium
    Eur Neuropsychopharmacol 16:233-40. 2006
  3. doi request reprint Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    J Clin Psychopharmacol 28:210-3. 2008
  4. ncbi request reprint Concordance of patient and clinical ratings of symptom severity and change of psychotic illness
    Jonathan Rabinowitz
    Schizophr Res 100:359-60. 2008
  5. ncbi request reprint Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
    Werner Kissling
    Klinikum rechts der Isar, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Munchen, Germany
    Hum Psychopharmacol 22:505-13. 2007
  6. ncbi request reprint Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone
    Max Schmauss
    Department of Psychiatry, Bezirkskrankenhaus Augsburg, Augsburg, Germany
    Int Clin Psychopharmacol 22:85-92. 2007
  7. ncbi request reprint Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    Schizophr Res 89:129-39. 2007
  8. ncbi request reprint [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]
    Steffen Heger
    Praxis für Psychosomatische Medizin und Psychotherapie, Koln
    Z Kinder Jugendpsychiatr Psychother 34:257-65. 2006
  9. ncbi request reprint Time course for antipsychotic treatment response in first-episode schizophrenia
    Robin Emsley
    Department of Social Work, Bar Ilan University, Ramat Gan, Israel
    Am J Psychiatry 163:743-5. 2006
  10. ncbi request reprint Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005

Collaborators

Detail Information

Publications13

  1. doi request reprint A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
    Rossella Medori
    Janssen Cilag EMEA, Neuss, Germany
    Biol Psychiatry 63:981-9. 2008
    ..There is increasing recognition of attention-deficit/hyperactivity disorder (ADHD) in adults and the need to evaluate efficacy and safety of methylphenidate treatment in these patients...
  2. ncbi request reprint Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable
    Rossella Medori
    Janssen Cilag, Medical Affairs EMEA, Beerse, Belgium
    Eur Neuropsychopharmacol 16:233-40. 2006
    ..m. every 2 weeks. The constant and slow release of the long-acting formulation leads to less fluctuation in plasma levels and to a D(2)-like receptor occupancy which is below the threshold for EPS...
  3. doi request reprint Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    J Clin Psychopharmacol 28:210-3. 2008
    ..5 mg for 30%, and 50 mg for 16%. This preliminary study suggests that RLAI was overall well tolerated and appears to be effective in recent-onset psychosis. Further investigation is warranted...
  4. ncbi request reprint Concordance of patient and clinical ratings of symptom severity and change of psychotic illness
    Jonathan Rabinowitz
    Schizophr Res 100:359-60. 2008
  5. ncbi request reprint Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
    Werner Kissling
    Klinikum rechts der Isar, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Munchen, Germany
    Hum Psychopharmacol 22:505-13. 2007
    ..This post-hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited...
  6. ncbi request reprint Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone
    Max Schmauss
    Department of Psychiatry, Bezirkskrankenhaus Augsburg, Augsburg, Germany
    Int Clin Psychopharmacol 22:85-92. 2007
    ..001). These results indicate that further improvement in symptom control can be seen after a change to risperidone long-acting injectable in clinically stable patients previously treated with oral risperidone...
  7. ncbi request reprint Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
    Robin Emsley
    University of Stellenbosch, Tygerberg, Cape Town, South Africa
    Schizophr Res 89:129-39. 2007
    ..Recently, the "Remission in Schizophrenia Working Group" proposed remission criteria consisting of a reduction to mild levels on key symptoms for at least 6 months...
  8. ncbi request reprint [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]
    Steffen Heger
    Praxis für Psychosomatische Medizin und Psychotherapie, Koln
    Z Kinder Jugendpsychiatr Psychother 34:257-65. 2006
    ..The objective was to evaluate the safety and efficacy of a switch in medication to a single daily dose of OROS-Methylphenidate (OROS-MPH, Concerta) in clinically stable children and adolescents with ADHD...
  9. ncbi request reprint Time course for antipsychotic treatment response in first-episode schizophrenia
    Robin Emsley
    Department of Social Work, Bar Ilan University, Ramat Gan, Israel
    Am J Psychiatry 163:743-5. 2006
    ..The authors examined early onset of antipsychotic action and early prediction of nonresponse to antipsychotics in patients with first-episode schizophrenia...
  10. ncbi request reprint Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005
    ..Direct initiation of RLAI was effective and well tolerated. RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy...
  11. ncbi request reprint Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis
    Joseph Lejeune
    CHR Citadelle, Liege, Belgium
    Int Clin Psychopharmacol 19:259-69. 2004
    ..m. conventional neuroleptic treatment with or without lorazepam. Oral risperidone plus lorazepam rapidly reduces symptoms, including aggression, and causes fewer EPS...
  12. ncbi request reprint Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies
    Glenn W Currier
    University of Rochester Medical Center, Rochester, New York, 14642, USA
    J Psychiatr Pract 12:30-40. 2006
    ..A synthesis of data from individual clinical trials, meta-analyses, review articles, and expert consensus recommendations is used to develop a working clinical algorithm for the acute management of aggression and agitation...
  13. ncbi request reprint [Tardive dyskinesia: pergolid, a possible therapeutic option]
    Alexander Diehl
    Zentralinstitut fur Seelische Gesundheit, Mannheim, Germany
    Psychiatr Prax 30:333-7. 2003
    ..Low-dose pergolide should activate presynaptic auto receptors, decrease dopamintransmission and reduce tardive dyskinesia...